Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Next Previous
Trial Profile

A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Prednisolone acetate
  • Indications Anterior uveitis
  • Focus Registrational; Therapeutic Use
  • Sponsors EyeGate Pharma; Kiora Pharmaceuticals

Most Recent Events

  • 04 Sep 2018 According to EyeGate Pharma media release, company announced top-line results from this trial.
  • 04 Sep 2018 Results published in the EyeGate Pharma Media Release
  • 04 May 2015 The US FDA provided guidance that if a confirmatory phase III trial of EGP-437 in anterior uveitis ((see trial profile 700255415) meets non-inferiority criteria, data from that trial along with data from this trial will be sufficient to support a New Drug Application (NDA) filing, according to an EyeGate Pharma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top